Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369066 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL3369088 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL3369085 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL832728 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL832727 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL13118170 | 0.90 | HDAC1 (0.82) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL3368919 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL3368922 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| Pracinostat SCHEMBL833106 | 0.88 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| Pracinostat SCHEMBL29351549 | 0.88 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | claimed |
| US-12618046-B2 | Generation of tumor immunity using astrocytes and astrocyte-dendritic cell combinations | VELTMEYER JAMES (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025264721-A1 | ENHANCEMENT OF REGENERATIVE ACTIVITY BY INACTIVATION OF SENESCENT CELLS | IMMORTA BIO, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250381230-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS AND REDUCING TAU PROTEIN AGGREGATES | SanBio Co. Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-20250361488-A1 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | UNIV RICE WILLIAM M (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025235998-A1 | PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNE MODULATORY ACTIVITY | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235744-A1 | TREATMENT OF LIVER FAILURE BY HEPATOGENIC MONOCYTES | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HDAC1 908/4885HDAC8 3157/4885HDAC3 2519/4885 |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 4/4885HDAC3 7/4885 |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC3 7/4885 |
| US-12618046-B2 | Generation of tumor immunity using astrocytes and astrocyte-dendritic cell combinations | CD44, TLR5, CD14 | HDAC1 3648/4885HDAC8 901/4885HDAC3 1652/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HDAC1 908/4885HDAC8 3157/4885HDAC3 2519/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | HDAC1 3908/4885HDAC8 2243/4885HDAC3 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.